GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » Scaled Net Operating Assets

Nanomix (Nanomix) Scaled Net Operating Assets : -2.41 (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Nanomix Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Nanomix's operating assets for the quarter that ended in Dec. 2022 was $0.97 Mil. Nanomix's operating liabilities for the quarter that ended in Dec. 2022 was $3.41 Mil. Nanomix's Total Assets for the quarter that ended in Sep. 2022 was $1.01 Mil. Therefore, Nanomix's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2022 was -2.41.


Nanomix Scaled Net Operating Assets Historical Data

The historical data trend for Nanomix's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanomix Scaled Net Operating Assets Chart

Nanomix Annual Data
Trend Dec20 Dec21 Dec22
Scaled Net Operating Assets
-81.68 -32.36 -2.70

Nanomix Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -5.70 -2.29 -2.08 -2.29 -2.41

Competitive Comparison of Nanomix's Scaled Net Operating Assets

For the Medical Devices subindustry, Nanomix's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanomix's Scaled Net Operating Assets Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanomix's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Nanomix's Scaled Net Operating Assets falls into.



Nanomix Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Nanomix's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2022 )
=(Operating Assets (A: Dec. 2022 )-Operating Liabilities (A: Dec. 2022 ))/Total Assets (A: Dec. 2021 )
=(0.965-3.409)/0.906
=-2.70

where

Operating Assets(A: Dec. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.982 - 0.017
=0.965

Operating Liabilities(A: Dec. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=14.815 - 10.111 - 1.295
=3.409

Nanomix's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2022 )
=(Operating Assets (Q: Dec. 2022 )-Operating Liabilities (Q: Dec. 2022 ))/Total Assets (Q: Sep. 2022 )
=(0.965-3.409)/1.013
=-2.41

where

Operating Assets(Q: Dec. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=0.982 - 0.017
=0.965

Operating Liabilities(Q: Dec. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=14.815 - 10.111 - 1.295
=3.409

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanomix Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Nanomix's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanomix (Nanomix) Business Description

Traded in Other Exchanges
N/A
Address
2121 Williams Street, San Leandro, CA, USA, 94577
Nanomix Corp develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. Its products include The Nanomix eLab System, COVID-19 Rapid Antigen Panel, and Critical Infection and Host Response. The company's products improve healthcare delivery by bringing the diagnostic information to the point of initial patient interaction, whether in the hospital or settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more.
Executives
Chris Hetterly officer: Chief Financial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Garrett Gruener director, 10 percent owner ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Thomas Schlumpberger director, officer: CEO C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Vidur Sahney officer: Chief Operating Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
John Hardesky officer: Chief Commercial Officer C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
David Ludvigson director, officer: CEO and President BLACK PEARL INC, 400 SECOND ST STE 450, SAN FRANCISCO CA 94107
Gregory T Schiffman director 1030 NW JOHNSON ST, UNIT 608, PORTLAND OR 97209
Loraine Upham officer: Chief Operating Officer C/O BOSTON THERAPEUTUCS INC., 354 MERRIMACK ST, #4, LAWRENCE MA 01843
Carl W Rausch director, officer: CEO
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Cheng Conroy Chi-heng director ADVANCE PHARMACEUTICAL CO LTD, 3/F, GMP CENTRE, 12 DAI FU STREET, TAI PO K3 280
Anthony Don Squeglia officer: Chief Financial Officer PRO-PHARMACEUTICALS, INC., 7 WELLS AVENUE, SUITE 34, NEWTON MA 02459
Neill Sydney Colin director C/O AXONYX INC, 500 SEVENTH AVE 1OTH FLOOR, NEW YORK NY 10018
Jonathan B Rome officer: Chief Operating Officer (3) 178 WEST SADDLE RIVER ROAD, SADDLE RIVER NJ 07458
Rom E Eliaz director 33 KACHAL STREET, LEHAVIM L3 85338

Nanomix (Nanomix) Headlines

From GuruFocus

Nanomix Announces Upgrade to OTCQB� Venture Market

By GuruFocusNews GuruFocusNews 06-02-2022

Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples

By GuruFocusNews GuruFocusNews 06-25-2022

Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples

By GuruFocusNews GuruFocusNews 05-26-2022

Nanomix Receives IVDR Certification for the eLab Analyzer

By PurpleRose PurpleRose 07-14-2022

Nanomix Announces Upgrade to OTCQB� Venture Market

By GuruFocusNews GuruFocusNews 06-12-2022

Nanomix Granted CE Mark for eLab S1 Assay Panel for Whole Blood Samples

By GuruFocusNews GuruFocusNews 06-05-2022

Nanomix Receives IVDR Certification for the eLab Analyzer

By GuruFocusNews GuruFocusNews 06-14-2022

Nanomix Announces Upgrade to OTCQB� Venture Market

By GuruFocusNews GuruFocusNews 06-22-2022